Blenrep |
Human |
belantamab mafodotin |
belantamab mafodotin |
EMEA/H/C/006511 |
GlaxoSmithKline Trading Services Limited |
2025/07/23
|
Authorised |
Emtricitabine / Tenofovir alafenamide Viatris |
Human |
emtricitabine;tenofovir alafenamide |
emtricitabine;tenofovir alafenamide fumarate |
EMEA/H/C/006469 |
Viatris Limited |
2025/07/18
|
Authorised |
Dazublys |
Human |
trastuzumab |
trastuzumab |
EMEA/H/C/006219 |
CuraTeQ Biologics s.r.o |
2025/06/30
|
Authorised |
Oczyesa |
Human |
octreotide |
octreotide hydrochloride |
EMEA/H/C/006322 |
Camurus AB |
2025/06/30
|
Authorised |
Ziihera |
Human |
zanidatamab |
zanidatamab |
EMEA/H/C/006380 |
Jazz Pharmaceuticals Ireland Limited |
2025/06/27
|
Authorised |
Sephience |
Human |
sepiapterin |
sepiapterin |
EMEA/H/C/006331 |
PTC Therapeutics International Limited |
2025/06/19
|
Authorised |
Tepezza |
Human |
teprotumumab |
teprotumumab |
EMEA/H/C/006396 |
Amgen Europe B.V. |
2025/06/19
|
Authorised |
Duvyzat |
Human |
givinostat |
givinostat hydrochloride monohydrate |
EMEA/H/C/006079 |
Italfarmaco S.p.A. |
2025/06/06
|
Authorised |
Qoyvolma |
Human |
ustekinumab |
ustekinumab |
EMEA/H/C/006649 |
Celltrion Healthcare Hungary Kft. |
2025/06/02
|
Authorised |
Osvyrti |
Human |
denosumab |
denosumab |
EMEA/H/C/006399 |
Accord Healthcare S.L.U. |
2025/05/26
|
Authorised |
Jubereq |
Human |
denosumab |
denosumab |
EMEA/H/C/006398 |
Accord Healthcare S.L.U. |
2025/05/26
|
Authorised |
Deqsiga |
Human |
human normal immunoglobulin |
human normal immunoglobulin |
EMEA/H/C/006423 |
Takeda Manufacturing Austria AG |
2025/05/02
|
Authorised |
Trabectedin Accord |
Human |
trabectedin |
trabectedin |
EMEA/H/C/006433 |
Accord Healthcare S.L.U. |
2025/04/25
|
Authorised |
Lynozyfic |
Human |
linvoseltamab |
linvoseltamab |
EMEA/H/C/006370 |
Regeneron Ireland Designated Activity Company (DAC) |
2025/04/23
|
Authorised |
Vyjuvek |
Human |
beremagene geperpavec |
Beremagene geperpavec |
EMEA/H/C/006330 |
Krystal Biotech Netherlands B.V. |
2025/04/23
|
Authorised |
Leqembi |
Human |
lecanemab |
Lecanemab |
EMEA/H/C/005966 |
Eisai GmbH |
2025/04/15
|
Authorised |
Datroway |
Human |
datopotamab deruxtecan |
datopotamab deruxtecan |
EMEA/H/C/006547 |
Daiichi Sankyo Europe GmbH |
2025/04/04
|
Authorised |
Dyrupeg |
Human |
pegfilgrastim |
pegfilgrastim |
EMEA/H/C/006407 |
CuraTeQ Biologics s.r.o |
2025/03/28
|
Authorised |
Tivdak |
Human |
tisotumab vedotin |
tisotumab vedotin |
EMEA/H/C/005363 |
Genmab A/S |
2025/03/28
|
Authorised |
Eltrombopag Accord |
Human |
eltrombopag |
eltrombopag olamine |
EMEA/H/C/006459 |
Accord Healthcare S.L.U. |
2025/03/28
|
Authorised |